- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)
This study looks at a new combination of two drugs, pembrolizumab and epacadostat, for advanced kidney cancer. It compares this combination to standard treatments (sunitinib or pazopanib) to see if it works better and is safe for adults.
For: Locally advanced/metastatic renal cell carcinomaSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype
This study compares two treatments for rare advanced sarcomas: a combination of nivolumab and ipilimumab, or pazopanib alone. It aims to see which treatment best stops the cancer from growing or spreading and helps people live longer.
For: Metastatic or unresectable advanced rare sarcomasFrance